Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR p.T790M status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.